Clinical Trial

Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)

Study acronym: BEAT
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
phase II controlled randomized study comparing atezolizumab as single agent to the combination of atezolizumab and bevacizumab in patients with chemonaive metastatic NSCLC with PD-L1 expression. All NSCLC patients with tumor tissue available for biomarker assessment and candidate for first-line therapy are considered eligible for the study. After evaluation of all inclusion and exclusion criteria and after informed consent signature all eligible patients will be randomized to atezolizumab (Arm A) or to the combination of atezolizumab and bevacizumab (Arm B). Disease assessment will be performed every 6 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2019-03-28.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-02-05
Trial Details
NCT Number NCT03896074
Lead Sponsor Fondazione Ricerca Traslazionale
Conditions Non-small-cell Lung Cancer Patients
Enrollment 206 participants
Start Date 2020-03-02
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-09